These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

598 related items for PubMed ID: 28288821

  • 21. Combination of 7-hydroxycoumarin in a platinum(IV) complex derived from cisplatin enhanced cytotoxicity with multiple mechanisms of action.
    Hua W, Zhao J, Hu W, Gou S.
    J Inorg Biochem; 2018 Sep; 186():17-23. PubMed ID: 29807243
    [Abstract] [Full Text] [Related]

  • 22. LYG-202 augments tumor necrosis factor-α-induced apoptosis via attenuating casein kinase 2-dependent nuclear factor-κB pathway in HepG2 cells.
    Chen FH, Lu N, Zhang HW, Zhao L, He LC, Sun HP, You QD, Li ZY, Guo QL.
    Mol Pharmacol; 2012 Nov; 82(5):958-71. PubMed ID: 22909797
    [Abstract] [Full Text] [Related]

  • 23. Engineering liposomal nanoparticles of cholesterol-tethered amphiphilic Pt(iv) prodrugs with prolonged circulation time in blood.
    Datta P, Bang S, Yue Z, Beach T, Stilgenbauer M, Wang H, Bowers DJ, Kurokawa M, Xiao H, Zheng YR.
    Dalton Trans; 2020 Jun 23; 49(24):8107-8113. PubMed ID: 32490446
    [Abstract] [Full Text] [Related]

  • 24. CK2 modulation of NF-kappaB, TP53, and the malignant phenotype in head and neck cancer by anti-CK2 oligonucleotides in vitro or in vivo via sub-50-nm nanocapsules.
    Brown MS, Diallo OT, Hu M, Ehsanian R, Yang X, Arun P, Lu H, Korman V, Unger G, Ahmed K, Van Waes C, Chen Z.
    Clin Cancer Res; 2010 Apr 15; 16(8):2295-307. PubMed ID: 20371694
    [Abstract] [Full Text] [Related]

  • 25. Efficient co-delivery of a Pt(IV) prodrug and a p53 activator to enhance the anticancer activity of cisplatin.
    Ma R, Wang Y, Yan L, Ma L, Wang Z, Chan HC, Chiu SK, Chen X, Zhu G.
    Chem Commun (Camb); 2015 May 07; 51(37):7859-62. PubMed ID: 25854514
    [Abstract] [Full Text] [Related]

  • 26. A novel pyrazole-containing indolizine derivative suppresses NF-κB activation and protects against TNBS-induced colitis via a PPAR-γ-dependent pathway.
    Fu Y, Ma J, Shi X, Song XY, Yang Y, Xiao S, Li J, Gu WJ, Huang Z, Zhang J, Chen J.
    Biochem Pharmacol; 2017 Jul 01; 135():126-138. PubMed ID: 28336257
    [Abstract] [Full Text] [Related]

  • 27. Dual-targeting tumor cells hybrids derived from Pt(IV) species and NF-κB inhibitors enables cancer therapy through mitochondrial dysfunction and ER stress and overcomes cisplatin resistance.
    Wang M, Li G, Jiang G, Cai J, Zhong W, Huang R, Liu Z, Huang X, Wang H.
    Eur J Med Chem; 2024 Feb 15; 266():116095. PubMed ID: 38215589
    [Abstract] [Full Text] [Related]

  • 28. Targeting RAS-RAF pathway significantly improves antitumor activity of Rigosertib-derived platinum(IV) complexes and overcomes cisplatin resistance.
    Liu Z, Wang M, Wang H, Fang L, Gou S.
    Eur J Med Chem; 2020 May 15; 194():112269. PubMed ID: 32248002
    [Abstract] [Full Text] [Related]

  • 29. Biotin-Pt (IV)-indomethacin hybrid: A targeting anticancer prodrug providing enhanced cancer cellular uptake and reversing cisplatin resistance.
    Hu W, Fang L, Hua W, Gou S.
    J Inorg Biochem; 2017 Oct 15; 175():47-57. PubMed ID: 28700961
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. A Pt(IV) Prodrug Combining Chlorambucil and Cisplatin: a Dual-Acting Weapon for Targeting DNA in Cancer Cells.
    Montagner D, Tolan D, Andriollo E, Gandin V, Marzano C.
    Int J Mol Sci; 2018 Nov 27; 19(12):. PubMed ID: 30486477
    [Abstract] [Full Text] [Related]

  • 32. CXCL12/CXCR4 axis confers adriamycin resistance to human chronic myelogenous leukemia and oroxylin A improves the sensitivity of K562/ADM cells.
    Wang Y, Miao H, Li W, Yao J, Sun Y, Li Z, Zhao L, Guo Q.
    Biochem Pharmacol; 2014 Aug 01; 90(3):212-25. PubMed ID: 24858801
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. LW-214, a newly synthesized flavonoid, induces intrinsic apoptosis pathway by down-regulating Trx-1 in MCF-7 human breast cells.
    Pan D, Li W, Miao H, Yao J, Li Z, Wei L, Zhao L, Guo Q.
    Biochem Pharmacol; 2014 Feb 15; 87(4):598-610. PubMed ID: 24374359
    [Abstract] [Full Text] [Related]

  • 35. Rational design of an AKR1C3-resistant analog of PR-104 for enzyme-prodrug therapy.
    Mowday AM, Ashoorzadeh A, Williams EM, Copp JN, Silva S, Bull MR, Abbattista MR, Anderson RF, Flanagan JU, Guise CP, Ackerley DF, Smaill JB, Patterson AV.
    Biochem Pharmacol; 2016 Sep 15; 116():176-87. PubMed ID: 27453434
    [Abstract] [Full Text] [Related]

  • 36. A cisplatin-based platinum(IV) prodrug containing a glutathione s-transferase inhibitor to reverse cisplatin-resistance in non-small cell lung cancer.
    Chen H, Wang X, Gou S.
    J Inorg Biochem; 2019 Apr 15; 193():133-142. PubMed ID: 30731264
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Monochalcoplatin: An Actively Transported, Quickly Reducible, and Highly Potent PtIV Anticancer Prodrug.
    Ma L, Wang N, Ma R, Li C, Xu Z, Tse MK, Zhu G.
    Angew Chem Int Ed Engl; 2018 Jul 16; 57(29):9098-9102. PubMed ID: 29806087
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 30.